Tryp Therapeutics Inc. (8FW.F)

0.0300 0.0000 (0.00%) As of 08:12AM CEST. Market open.

Tryp Therapeutics Inc.

301 - 1665 Ellis Street
Kelowna, BC V1Y 2B3
Canada
833-811-8797
https://www.tryptherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. James S. Kuo M.B.A., M.D.	Co-Founder & Director	18.21k	N/A	1965
Mr. Peter Molloy ASIP, B.A., C.F.A.	Chief Business Officer & Director	125.37k	N/A	1972
Mr. Jason Carroll	CEO & Director	N/A	N/A	N/A
Dr. James P. Gilligan MSIB, Ph.D.	President & Chief Scientific Officer	215.7k	N/A	1952
Dr. William James Garner M.D., M.P.H., MPH	Founder & MD	38.53k	N/A	1966
Mr. Jim O'Neill	Chief Financial Officer	N/A	N/A	N/A
Mr. Sidney Taubenfeld R.Ph	Chief Operating Officer	33.26k	N/A	N/A
Ms. Joy Willis	Director of Investor Relations	N/A	N/A	N/A
Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1949

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.

Corporate Governance

Tryp Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.